173 related articles for article (PubMed ID: 33763790)
1. Excess heart age in young breast cancer survivors over 2-year follow-up.
Vo JB; Kenzik KM; Landier W; Raju D; Kirklin JK; Meneses K
Cancer Causes Control; 2021 Jun; 32(6):617-626. PubMed ID: 33763790
[TBL] [Abstract][Full Text] [Related]
2. Implications of excess weight in the cardiotoxicity of anthracyclines and trastuzumab in breast cancer.
Guenancia C; Ladoire S; Ghiringelli F; Rochette L; Vergely C; Cottin Y
Arch Cardiovasc Dis; 2017 Feb; 110(2):69-71. PubMed ID: 28216265
[No Abstract] [Full Text] [Related]
3. Changes in Cardiovascular Biomarkers With Breast Cancer Therapy and Associations With Cardiac Dysfunction.
Demissei BG; Hubbard RA; Zhang L; Smith AM; Sheline K; McDonald C; Narayan V; Domchek SM; DeMichele A; Shah P; Clark AS; Fox K; Matro J; Bradbury AR; Knollman H; Getz KD; Armenian SH; Januzzi JL; Tang WHW; Liu P; Ky B
J Am Heart Assoc; 2020 Jan; 9(2):e014708. PubMed ID: 31959034
[TBL] [Abstract][Full Text] [Related]
4. Cardio-oncology, the myth of Sisyphus, and cardiovascular disease in breast cancer survivors.
Mavrogeni SI; Sfendouraki E; Markousis-Mavrogenis G; Rigopoulos A; Noutsias M; Kolovou G; Angeli C; Tousoulis D
Heart Fail Rev; 2019 Nov; 24(6):977-987. PubMed ID: 31134427
[TBL] [Abstract][Full Text] [Related]
5. Association of body mass index and cardiotoxicity related to anthracyclines and trastuzumab in early breast cancer: French CANTO cohort study.
Kaboré EG; Guenancia C; Vaz-Luis I; Di Meglio A; Pistilli B; Coutant C; Cottu P; Lesur A; Petit T; Dalenc F; Rouanet P; Arnaud A; Arsene O; Ibrahim M; Wassermann J; Boileau-Jolimoy G; Martin AL; Lemonnier J; André F; Arveux P
PLoS Med; 2019 Dec; 16(12):e1002989. PubMed ID: 31869400
[TBL] [Abstract][Full Text] [Related]
6. Obesity As a Risk Factor for Anthracyclines and Trastuzumab Cardiotoxicity in Breast Cancer: A Systematic Review and Meta-Analysis.
Guenancia C; Lefebvre A; Cardinale D; Yu AF; Ladoire S; Ghiringhelli F; Zeller M; Rochette L; Cottin Y; Vergely C
J Clin Oncol; 2016 Sep; 34(26):3157-65. PubMed ID: 27458291
[TBL] [Abstract][Full Text] [Related]
7. Cardiotoxicity and Cardiac Monitoring Among Chemotherapy-Treated Breast Cancer Patients.
Henry ML; Niu J; Zhang N; Giordano SH; Chavez-MacGregor M
JACC Cardiovasc Imaging; 2018 Aug; 11(8):1084-1093. PubMed ID: 30092967
[TBL] [Abstract][Full Text] [Related]
8. Cardiotoxicity screening of long-term, breast cancer survivors-The CAROLE (Cardiac-Related Oncologic Late Effects) Study.
Puckett LL; Saba SG; Henry S; Rosen S; Rooney E; Filosa SL; Gilbo P; Pappas K; Laxer A; Eacobacci K; Kapyur AN; Robeny J; Musial S; Chaudhry A; Chaudhry R; Lesser ML; Riegel A; Ramoutarpersaud S; Rahmani N; Shah A; Papas V; Dawodu T; Charlton J; Knisely JPS; Lee L
Cancer Med; 2021 Aug; 10(15):5051-5061. PubMed ID: 34245128
[TBL] [Abstract][Full Text] [Related]
9. High-sensitive troponin T assay can predict anthracycline- and trastuzumab-induced cardiotoxicity in breast cancer patients.
Kitayama H; Kondo T; Sugiyama J; Kurimoto K; Nishino Y; Kawada M; Hirayama M; Tsuji Y
Breast Cancer; 2017 Nov; 24(6):774-782. PubMed ID: 28434150
[TBL] [Abstract][Full Text] [Related]
10. Anthracycline and trastuzumab-induced cardiotoxicity in breast cancer.
Nicolazzi MA; Carnicelli A; Fuorlo M; Scaldaferri A; Masetti R; Landolfi R; Favuzzi AMR
Eur Rev Med Pharmacol Sci; 2018 Apr; 22(7):2175-2185. PubMed ID: 29687878
[TBL] [Abstract][Full Text] [Related]
11. Characteristics and Outcomes of Women Developing Heart Failure After Early Stage Breast Cancer Chemotherapy: A Population-Based Matched Cohort Study.
Abdel-Qadir H; Tai F; Croxford R; Austin PC; Amir E; Calvillo-Argüelles O; Ross H; Lee DS; Thavendiranathan P
Circ Heart Fail; 2021 Jul; 14(7):e008110. PubMed ID: 34187164
[TBL] [Abstract][Full Text] [Related]
12. Is screening for abnormal ECG patterns justified in long-term follow-up of childhood cancer survivors treated with anthracyclines?
Pourier MS; Mavinkurve-Groothuis AM; Loonen J; Bökkerink JP; Roeleveld N; Beer G; Bellersen L; Kapusta L
Pediatr Blood Cancer; 2017 Mar; 64(3):. PubMed ID: 27654133
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal changes of right ventricular deformation mechanics during trastuzumab therapy in breast cancer patients.
Keramida K; Farmakis D; Bingcang J; Sulemane S; Sutherland S; Bingcang RA; Ramachandran K; Tzavara C; Charalampopoulos G; Filippiadis D; Kouris N; Nihoyannopoulos P
Eur J Heart Fail; 2019 Apr; 21(4):529-535. PubMed ID: 30811091
[TBL] [Abstract][Full Text] [Related]
14. Nine-Year Median Follow-up of Cardiotoxicity and Efficacy of Trastuzumab Concurrently With Anthracycline-Based and Anthracycline-Free Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer Patients.
He X; Dai X; Ji J; Liu H; Shi G; Yeung SJ
Clin Breast Cancer; 2022 Jan; 22(1):e80-e90. PubMed ID: 34312098
[TBL] [Abstract][Full Text] [Related]
15. Late cardiac effect of anthracycline therapy in physically active breast cancer survivors - a prospective study.
Nagy AC; GulAcsi-BArdos P; CserEp Z; Hangody L; Forster T
Neoplasma; 2017; 64(1):92-100. PubMed ID: 27881009
[TBL] [Abstract][Full Text] [Related]
16. Long-term Cardiopulmonary Consequences of Treatment-Induced Cardiotoxicity in Survivors of ERBB2-Positive Breast Cancer.
Yu AF; Flynn JR; Moskowitz CS; Scott JM; Oeffinger KC; Dang CT; Liu JE; Jones LW; Steingart RM
JAMA Cardiol; 2020 Mar; 5(3):309-317. PubMed ID: 31939997
[TBL] [Abstract][Full Text] [Related]
17. A randomized trial to evaluate the impact of exercise-based cardiac rehabilitation for the prevention of chemotherapy-induced cardiotoxicity in patients with breast cancer: ONCORE study protocol.
Díaz-Balboa E; González-Salvado V; Rodríguez-Romero B; Martínez-Monzonís A; Pedreira-Pérez M; Palacios-Ozores P; López-López R; Peña-Gil C; González-Juanatey JR
BMC Cardiovasc Disord; 2021 Apr; 21(1):165. PubMed ID: 33827450
[TBL] [Abstract][Full Text] [Related]
18. Decline in Left Ventricular Ejection Fraction Following Anthracyclines Predicts Trastuzumab Cardiotoxicity.
Goel S; Liu J; Guo H; Barry W; Bell R; Murray B; Lynch J; Bastick P; Chantrill L; Kiely BE; Abdi E; Rutovitz J; Asghari R; Sullivan A; Harrison M; Kohonen-Corish M; Beith J
JACC Heart Fail; 2019 Sep; 7(9):795-804. PubMed ID: 31401102
[TBL] [Abstract][Full Text] [Related]
19. Factors predicting trastuzumab-related cardiotoxicity in a real-world population of women with HER2+ breast cancer.
Naumann D; Rusius V; Margiotta C; Nevill A; Carmichael A; Rea D; Sintler M
Anticancer Res; 2013 Apr; 33(4):1717-20. PubMed ID: 23564821
[TBL] [Abstract][Full Text] [Related]
20. Cardiotoxicity of Targeted Cancer Drugs: Concerns, "The Cart Before the Horse," and Lessons from Trastuzumab.
Menna P; Minotti G; Salvatorelli E
Curr Cardiol Rep; 2019 Mar; 21(5):33. PubMed ID: 30887161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
